Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merz North America, Inc.
With
Merz Pharmaceuticals GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatients (male or female) 18 years of age or older.
Horizontal forehead lines (HFL), glabellar frown lines (GFL), and symmetrical lateral canthal lines (LCL) of moderate to severe intensity at maximum contraction as assessed by the investigator and subject according to Merz Aesthetics Scales (MAS).
You may not be if
Previous treatment with botulinum neurotoxin (BoNT) of any serotype in the face within the last 12 months before injection.
Any facial cosmetic procedure within the last 12 months before baseline injection.
Previous treatment with any biodegradable filler in the face within the last 12 months before injection.
Any previous insertion of permanent material in the face (regardless of the time between previous treatment and this study).
Any medical condition that may put the subject at increased risk with exposure to NT201.
Clareo Health | Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
